Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Kuleshova EV et al.  
Efficacy of slow-release Nifedipine, Talinolol and combination in Angina Pectoris (NITAAP)

Journal of Clinical and Basic Cardiology 2000; 3 (1): 29-34

PDF    Summary    Figures   

Fig. 1: NITAAP-Studie Fig. 2: NITAAP-Studie Fig. 3: NITAAP-Studie Fig. 4: NITAAP-Studie Fig. 5: NITAAP-Studie Fig. 6: NITAAP-Studie

Keywords: Angina pectorisBetablockerKombinationstherapieNifedipintalinololAngina pectorisbeta-blockercombination therapynifedipinetalinolol

Efficacy of slow-release formulation of nifedipine (Corinfar® retard) and talinolol (Cordanum® 100), both as monotherapy and in combination, was investigated in 45 patients with effort-induced angina. The drugs were introduced/withdrawn in the following order: ? nifedipine monotherapy 20 mg then 2 x 20 mg daily; ? nifedipine/talinolol combination therapy 20 mg daily/100 mg daily then 2 x 20 mg/2 x 100 mg daily; ? talinolol monotherapy 2 x 100 mg daily. Compared with baseline, the number of angina attacks, nitroglycerine consumption, and blood pressure all significantly decreased, while exercise tolerance increased during all treatments. The dose-related anti-anginal effect of nifedipine was demonstrated. The efficacy of nifedipine 40 mg and talinolol 200 mg monotherapies was similar; the maximal effect was seen in patients treated with the higher dose combination of nifedipine 40 mg and talinolol 200 mg. However, with this higher dose combination therapy, the incidence of adverse events was higher. In general, talinolol was well tolerated. The double product values (heart rate x systolic blood pressure/100) significantly decreased during high-dose combination therapy and talinolol monotherapy compared with baseline, but revealed differences between patients during high-dose nifedipine monotherapy. J Clin Basic Cardiol 2000; 3: 29-34.
copyright © 2000–2024 Krause & Pachernegg GmbH | Sitemap | Datenschutz | Impressum